One of the goals of WP 3 was to map how the process for authorization of animal experiments is organized in different Member States. This task, has been completed and the results are available on this website (link). The results show the wide variation in organization across the Member States. The next steps for WP3 consist of an analysis of how this difference impacts upon the operation of the Directive. This work package will furthermore contribute to the development of instruments for information exchange between ethics committees across Member States.
WP3 is chaired by Anna Olsson, IBMC - Institute for Molecular and Cell Biology, Porto, Portugal. She can be contacted via email@example.com. For more information on the people behind this work package click here.
Who evaluates the ethical acceptability of animal research?:
Has Directive 2010/63/EU resulted in a more harmonized evaluation process across Europe?:
Current related activities of WP3 members:
- Anna Olsson gave a talk at the FELASA Congress in Brussels in June 2016, entitled ANIMPACT: Mapping European diversity under Directive 2010/63/EU and proposing tools to increase dialoque. The abstract can be found here.
Anna Olsson gave two talks at the 16th annual EUSAAT conference in Linz in September 2015.
- The the abstract of the talk Harm-benefit analysis of animal experimentation: a qualitative study of ethics committee practice in six European countries can be found here or in the conference abstractbook which is availabe here.
- The abstract of the talk entitled Ethics review of animal experiments in Europe under Directive 2010/63/EU can be found here or in the conference abstractbook which is availabe here.